Anna Samakidou

Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19

M. Vlychou, E. Giamarellos‐Bourboulis, G. Dalekos, 2021, European Journal of Internal Medicine.

First Results From a Propensity Matching Trial of Mycophenolate Mofetil vs. Azathioprine in Treatment-Naive AIH Patients

E. Rigopoulou, G. Dalekos, N. Gatselis, 2022, Frontiers in Immunology.

Complement C3 inhibition in severe COVID-19 using compstatin AMY-101

John D Lambris, B. Nilsson, S. Iacobelli, 2022, Science advances.

Long-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis

E. Rigopoulou, G. Dalekos, N. Gatselis, 2022, JHEP reports : innovation in hepatology.

Soluble IL-2R Levels at Baseline Predict the Development of Severe Respiratory Failure and Mortality in COVID-19 Patients

K. Antoniou, D. Sagris, G. Dalekos, 2022, Viruses.

MBL deficiency-causing B allele (rs1800450) as a risk factor for severe COVID-19

C. Hadjichristodoulou, V. Mouchtouri, G. Germanidis, 2021, Immunobiology.

Radiologic Features of T10 Paravertebral Muscle Sarcopenia: Prognostic Factors in COVID-19

M. Vlychou, Christos G Gogos, C. Kalogeropoulou, 2023, Journal of Clinical Medicine Research.